Galimedix to present eDREAM Phase 2 GA data at EURETINA 2026
Galimedix Therapeutics has announced that functional feasibility data from its Phase 2 eDREAM study, evaluating oral candidate GAL-101 in geographic atrophy (GA), will be presented at the 26th EURETINA Congress in Vienna, Austria, running 1-4 October 2026.
The privately held, US-German biotech will deliver four oral presentations and two e-posters, all drawing on baseline data from the eDREAM trial. The headline presentation, delivered by chief medical officer Yaniv Barkana, will cover the repeatability and test-retest characteristics of patient-tailored microperimetry endpoints in non-foveal GA, the company said. Microperimetry measures visual sensitivity at specific retinal locations and is being positioned by Galimedix as a sensitive functional endpoint that could better capture treatment effects than conventional visual acuity measures alone.
GA is an advanced, irreversible form of dry age-related macular degeneration (AMD) characterised by progressive photoreceptor and retinal pigment epithelium loss. It affects millions of people globally and causes significant central vision loss. The condition has historically lacked effective treatments, though the competitive picture has shifted.
Competitive and regulatory context
Two complement-pathway inhibitors, pegcetacoplan (Syfovre, from Apellis Pharmaceuticals) and avacincaptad pegol (Izervay, from Astellas), have both received FDA approval for GA since 2023, representing the first approved therapies in the indication. Both are delivered by intravitreal injection, which creates a meaningful clinical differentiator for Galimedix's oral approach with GAL-101 if efficacy can be established. Patient preference data consistently show significant reluctance around repeat ocular injections, and an effective oral option could command strong uptake if it clears regulatory hurdles.
GAL-101 targets amyloid beta aggregation, a mechanism the company believes is relevant not only in GA and glaucoma but also in Alzheimer's disease. This cross-indication hypothesis is scientifically plausible given the presence of amyloid deposits in both the retina and the brain, though it remains unproven in late-stage trials and the relationship between amyloid and neurodegeneration is actively debated in the Alzheimer's field.
What the EURETINA data does and does not show
It is important to note that the EURETINA presentations cover baseline and methodological data from eDREAM, not efficacy outcomes. The abstracts address topics including structure-function discordance in the peri-atrophic zone, cross-modal imaging agreement between fundus autofluorescence and optical coherence tomography, and visual acuity repeatability at baseline. These are largely endpoint-validation analyses, providing insight into trial design quality rather than signalling whether GAL-101 slows GA progression.
Investigators from Moorfields Ophthalmic Reading Centre and Clinical AI Lab at Moorfields Eye Hospital, as well as from Tel-Aviv Medical Center, are named as presenters, indicating a broad academic collaboration supporting the trial.
Galimedix has not disclosed a timeline for topline efficacy readout from eDREAM, nor has it announced any financing round or development partner in this release. As a private company, it gives limited visibility on its cash runway. Readers tracking this programme should watch for the primary efficacy data presentation, which will be the inflection point determining GAL-101's future development path and the company's ability to attract partnership or investment interest in a now-crowded GA landscape.